An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease . Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent . Throughout the late seventies and the eighties, important research initiatives developed stable mesalazine formulations like the eudragit-S coating of Asacol brand mesalazine and the Pentasa brand's encapsulation of mesalazine within microgranules . In the present day, contemporary research regarding novel methods to stabilize mesalazine continues and interest in the agent's capacity to decrease inflammatory activity and subsequently potentially reduce the risk of colorectal cancer in conditions like ulcerative colitis is maintained.
适用于溃疡性结肠炎和克罗恩病(Crohn病)。
Research Facility, Monroe, Wisconsin, United States
Research Site, Chesapeake, Virginia, United States
Imelda General Hospital Dept of Gastroenterology, Bonheiden, Belgium
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Evangelisches Krankenhaus Kalk, Cologne, Germany
Center of digestive diseases, Hamburg, Germany
Research Facility, Zaporizhzhya, Ukraine
Research FacilityPanevezys, Panevezys, Lithuania
Morristown Memorial Hospital/Goyerb Children's Hospital, Morristown, New Jersey, United States
Ev. Krankenhaus Hattingen GmbH, Hattingen, Germany
Research Site, Seattle, Washington, United States
UZ Gent, Gent, Belgium
Heilig Hart Ziekenhuis, Roeselaere, Belgium
Gastroenterologie MUDr.V.Abrahámová, Poděbrady, Czech Republic
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.